找化学品上960化工网!
960化工网

表阿霉素 | 56420-45-2

表阿霉素结构式图片|56420-45-2结构式图片
表阿霉素
Epirubicin
56420-45-2
C27H29NO11
543.51926
如需查看该化合物的详细结构式,mol文件,smile,InChi 请点击:表阿霉素结构式
41867
表阿霉素价格
简介
表阿霉素属于抗生素类抗肿瘤药。为阿霉素的同分异构体,作用机制是直接嵌入DNA核碱对之间,干扰转录过程,阻止mRNA的形成,从而抑制DNA和RNA的合成。此外,表阿霉素对拓朴异构酶Ⅱ也有抑制作用。为一细胞周期非特异性药物,对多种移植性肿瘤均有效。与阿霉素相比,疗效相等或略高,但对心脏的毒性较小。
名称和标识符
MDL MFCD01713214
InChIKey AOJJSUZBOXZQNB-VTZDEGQISA-N
Inchi InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22-,27-/m0/s1
SMILES O=C(C1=C2C(O)=C3[C@@H](O[C@@]4([H])C[C@H](N)[C@@H](O)[C@H](C)O4)C[C@@](C(CO)=O)(O)CC3=C1O)C5=CC=CC(OC)=C5C2=O
别名信息
- 中文别名 -
  • 表阿霉素
  • 表柔比星(表阿霉素)
  • 表比星
  • 表柔比星
  • 表阿霉霉
  • (8S,10S)-10-[(3'-氨基-2',3',6'-三脱氧-alpha-L-阿拉伯吡喃糖基)-O-]-6,8,11-三羟基-8-羟乙酰基-1-甲氧基-7,8,9,10-四氢并四苯-5,12-二酮
  • 表柔吡星
  • 10-[(3-氨基-2,3,6-三脱氧-Α-L-阿式-己吡喃糖基)氧]-7,8,9,10-四氢-6,8,11-三羟基-8-(羟乙酰基)-甲氧基-(8S-CIS)-并四苯-5,12-二酮
  • 表柔比星、表阿霉素、表比星
- 英文别名 -
  • Epirubicin
  • 10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8s-)oxy)-9
  • 4’-epiadriamycin
  • epi-dx
  • imi28
  • 5,12-Naphthacenedione, 10-(3-amino-2,3,6-trideoxy-.alpha.-L-arabino-hexopyranosyl)oxy-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-
  • 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-a-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)-
  • Epi-doxorubicin
  • 4'-epiadriamycin
  • 4'-Epi-DX
  • Adriblastin
  • Epiadriamycin
  • Farmarubicin
  • farmorubicin
  • Pidorubicin
  • WP 697
  • 5,12-Naphthacenedione,10-[(3-amino-2,3,6-trideoxy-a-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-,(8S,10S)- (9CI)
  • 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-a-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-,(8S-cis)-
  • 4'-Epidoxorubicin
  • 4'-epi-Adriamycin
  • 4'-epi-Doxorubicin
  • Epidoxorubicin
  • Farmarubicine
  • NSC 256942
  • Pharmarubicin
  • (8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxynaphthacene-5,12-dione
  • (8S-cis)-10-((3-Amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
  • Ellence
  • EPIRUBICIN [WHO-DD]
  • 4' Epi Adriamycin
  • Pidorubicinum (Latin)
  • AB00698552-14
  • EPIRUBICIN [INN]
  • Farmorubicin
  • AB00698552_15
  • Epirubicina (INN-Spanish)
  • DM6
  • Epirubicine [INN-French]
  • Epirubicin [INN:BAN]
  • (8S,10S)-10-{[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione
  • Epirubicina [Spanish]
  • Epirubicinum [Latin]
  • Pidorubicinum
  • 4' Epidoxorubicin
  • BRD-K04548931-003-16-5
  • Epirubicin free base
  • EPIRUBICIN [VANDF]
  • 4' Epi DXR
  • DTXSID0022987
  • NCGC00263918-08
  • HY-13624
  • 4-Epidoxorubicin
  • Epirubicinum [INN-Latin]
  • Acid, 8
  • D07901
  • EPIRUBICIN [HSDB]
  • 3-Glycoloyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl-3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
  • (8S,10S)-10-(((2R,4S,5R,6S)-4-Amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione
  • AB00698552-11
  • DM2
  • 4'-epidoxorubicin
  • Q425122
  • Epirubicina [INN-Spanish]
  • UNII-3Z8479ZZ5X
  • Epirubicine
  • BRN 1445813
  • 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-.alpha.-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)-
  • 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy-7,8,9,10-tetrahydro -6,8,(8S-cis)-
  • NSC-256942
  • Pidorubicina [INN-Spanish]
  • (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
  • IMI 28
  • (7S,9S)-7-[(2R,4S,5R,6S)-4-azanyl-6-methyl-5-oxidanyl-oxan-2-yl]oxy-4-methoxy-6,9,11-tris(oxidanyl)-9-(2-oxidanylethanoyl)-8,10-dihydro-7H-tetracene-5,12-dione
  • 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-
  • CCRIS 2261
  • (7S,9S)-7-[[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyl-2-oxanyl]oxy]-6,9,11-trihydroxy-9-(2-hydroxy-1-oxoethyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
  • AB00698552_16
  • Pidorubicine [INN-French]
  • BDBM43839
  • 4' Epiadriamycin
  • Pidorubicinum (INN-Latin)
  • HSDB 6962
  • Pidorubicina (INN-Spanish)
  • Epirubicine (INN-French)
  • 4'-Epiadriamycin
  • Farmorubicin (TN)
  • (1S,3S)-3-GLYCOLOYL-1,2,3,4,6,11-HEXAHYDRO-3,5,12-TRIHYDROXY-10-METHOXY-6,11-DIOXO-1-NAPHTHACENYL 3-AMINO-2,3,6-TRIDEOXY-alpha-L-ARABINO-HEXOPYRANOSIDE
  • Epirubicina
  • SBI-0206890.P001
  • SCHEMBL8582
  • Pidorubicinum [INN-Latin]
  • (7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
  • AB00698552-13
  • L01DB03
  • NCGC00263918-04
  • NS00069619
  • Epi DX
  • 4' Epi Doxorubicin
  • EPIRUBICIN [MI]
  • Epirubicin (INN)
  • A831042
  • DTXCID202987
  • 5,12-NAPHTHACENEDIONE, 10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-ARABINO-HEXOPYRANOSYL)OXY)-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-8-(HYDROXYACETYL)-1-METHOXY-, (8S-CIS)-
  • Pidorubicina
  • DB00445
  • Epirubicine [French]
  • 4'-epi DX
  • Epirubicinum
  • (7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
  • (1S,3S)-3-GLYCOLOYL-1,2,3,4,6,11-HEXAHYDRO-3,5,12-TRIHYDROXY-10-METHOXY-6,11-DIOXO-1-NAPHTHACENYL 3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-ARABINO-HEXOPYRANOSIDE
  • (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
  • (7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
  • Epirubicinum (Latin)
  • Pidorubicine
  • Epi-DX
  • 56420-45-2
  • 3Z8479ZZ5X
  • NSC256942
  • Ridorubicin
  • CHEBI:47898
  • CHEMBL417
  • 5,12-Naphthacenedione,10-[(3-amino-2,3,6-trideoxy-a-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-
  • 56420-45-2 (FREE BASE)
  • EN300-7410311
  • Pidorubicine (INN-French)
  • 4'-Epi-DXR
  • 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-
  • Epirubicinum (INN-Latin)
  • 10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione
  • NSC169534
  • FI-106
  • NSC-272332
  • NSC-307243
  • 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-
  • GNF-Pf-2453
  • Ferrate(1-),3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione]decachlorotri-, hydrogen, (8S-cis)-
  • SCHEMBL233853
  • NSC321796
  • FT-0630692
  • FT-0656147
  • 5, 10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-, mixt. with native calf thymus DNA
  • Adriamycin hydrochloride (Salt/Mix)
  • Triferric doxorubicin
  • DOX HCl (Salt/Mix)
  • Adriamycin-DNA hydrochloride
  • 7-(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
  • NSC307242
  • NSC-303831
  • FT-0601614
  • Neuro_000057
  • NSC-307242
  • ADR (Salt/Mix)
  • NSC272332
  • NSC-169534
  • NSC302662
  • NSC-272708
  • BRD-A76941896-001-01-6
  • NSC272707
  • (8S,10S)-10-[[(2R,4S,5S,6S)-4-Amino-5-hydroxy-6-methyl-2-tetrahydropyranyl]oxy]-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione
  • AOJJSUZBOXZQNB-UHFFFAOYSA-N
  • 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-
  • ADM
  • Doxorubicin hydrochloride (Salt/Mix)
  • 7-[(4-amino-5-hydroxy-6-methyl-2-oxanyl)oxy]-6,9,11-trihydroxy-9-(2-hydroxy-1-oxoethyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
  • Adriamycin Fe3Cl10 H
  • NSC307243
  • NSC-303830
  • SY224845
  • BRD-A76941896-003-01-2
  • Ferrate (1-),3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione]decachlorotri-, hydrogen, (8S-cis)
  • NSC303830
  • Nucleic acid, sodium salt, compound with (8S-cis)-10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione hydrochloride
  • BRD-A76941896-003-02-0
  • Q27163668
  • 3-Glycoloyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl 3-amino-2,3,6-trideoxy-L-lyxo-hexopyranoside, (1S,3S)-
  • 3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-1-naphthacenyl 3-amino-2,3,6-trideoxyhexopyranoside
  • (8S,10S)-10-[(3-Amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione
  • NSC-302662
  • CHEMBL263733
  • NSC-321796
  • MFCD00869292
  • NSC272708
  • NSC-272707
  • Dextran,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
  • Neuro_000121
  • CHEBI:91872
  • AKOS005434002
  • NSC267703
  • NSC303831
物化性质
实验特性
LogP 0.70160
PSA 206.07000
折射率 1.6400 (estimate)
沸点 617.77°C (rough estimate)
熔点 Not available
蒸气压 Not available
闪点 Not available
密度 1.3783 (rough estimate)
计算特性
精确分子量 543.17400
氢键供体数量 6
氢键受体数量 12
可旋转化学键数量 5
同位素质量 543.174061
重原子数量 39
复杂度 977
同位素原子数量 0
确定原子立构中心数量 6
不确定原子立构中心数量 0
确定化学键立构中心数量 0
不确定化学键立构中心数量 0
共价键单元数量 1
疏水参数计算参考值(XlogP)
互变异构体数量 81
表面电荷 0
拓扑分子极性表面积 206
国际标准相关数据
EINECS None
生产方法和用途
用途 抗肿瘤药物。
生产方法 化合物(I)经三氟乙酸酐N-酰化,以对氨基进行保护,得到化合物(Ⅱ)。再氧化为酮(Ⅲ),然后还原为醇(Ⅳ)。在酸作用下去除醚键,再经三氟乙酸酐酯化为化合物(Ⅵ),然后进行选择性氯代,得到所需的侧链(VII)。 化合物(Ⅷ)经二甲缩丙酮反应成缩酮(Ⅸ),然后和上述制得的侧链(Ⅶ)反应,得到的化合物(X)水解,即得表柔比星。
专业数据库参考
PubChemId 41867
化合物详情(旧版)

表阿霉素SMILES

OCC(=O)[C@]1(O)CC2C([C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](N)C3)C1)=C(O)C4=C(C(=O)C5=C(C(OC)=CC=C5)C4=O)C=2O

概述

表阿霉素(Epirubicin)是临床选择治疗实体瘤的药物之一,它直接作用于DNA,干扰并阻止DNA的复制和转录。其通过抑制琥珀酸氧化酶、NADPH-氧化酶等呼吸酶的活性而影响线粒体的功能。研究发现,其有诱导癌细胞凋亡的作用,可能通过凋亡的线粒体途径发生作用。由于其经肝胆系统排泄,故肝功能不全者应减量,以免蓄积中毒;中度肝功能受损患者(胆红素1.4~3mg/100ml或BSP滞留量9~15%),药量应减少50%;重度肝功能受损患者(胆红素>3mg/100ml或BSP滞留量>15%),药量应减少75%;中度肾功能受损患者无需减少剂量,因为仅少量的药物经肾脏排出。用法为静脉给药。建议先注入生理盐水检查输液管通畅性及注射针头确实在静脉内之后,再经此通畅的输液管给药。这一方法可减少药物外溢的危险,并确保给药后静脉用盐水冲洗。表阿霉素注射时溢出静脉会造成组织的严重损伤甚至坏死,小静脉注射或反复注射同一血管会造成静脉硬化;其不可与肝素混合,因为二者化学性质不配伍,在一定浓度时会发生沉淀反应;其可与其他抗肿瘤药物合用,但表阿霉素用量应减低,不应在同一注射器中混合药物。
表阿霉素为蒽环类抗生素,为阿霉素的同分异构体。主要作用机理是直接嵌入DNA 碱基对之间,干扰转录过程,阻止mRNA的形成而起抗肿瘤作用。既可抑制DNA的合成,又可抑制RNA的合成,故对细胞周期各阶段均有作用,为一细胞周期非特异性药物。对细胞膜和转运系统也有作用,但最主要的作用部位是细胞核,从而产生细胞毒作用。本品在体外可抑制小鼠胚胎成纤维细胞增生,体内对动物肉瘤S180腹水型和实体型以及Gross白血病有抗肿瘤作用,对试验性L1210和P388乳腺癌和Lewis肺癌也有效。

药代动力学

在组织内分布与阿霉素类似,进入体内迅速分布于心、肾、肝、脾、肺等组织,不能透过脑血屏障。给药后1小时、24 小时、48小时,在心脏和脾脏中浓度均低于阿霉素。48小时后肾脏中浓度也较阿霉素低。给药后1小时和6小时,肿瘤组织中浓度与阿霉素相当,在24小时和28小时后则较阿霉素高。在体内较阿霉素代谢、排泄快,主要经肝自胆道排出。血浆消除半衰期为30~40小时。血浆清除率约为0.9~1.14L/min。

表阿霉素物理化学性质

化学性质    盐酸表柔比星(Epirubicin Hydrochloride):C27H29 NO11?HCI。[56390-09-1]。橘红色结晶,熔点185℃(分解)。 [α]D20+274°(C=0.01,甲醇)。溶液应避光保存。

不良反应

1.骨髓抑制,主要表现为白细胞、血小板减少,但较轻,骨髓毒性与剂量增加有关。 
2.心脏毒性较阿霉素为低,主要为心律失常和ST-T段改变,一般可自行恢复。累积剂量超过 1000mg/m2时,可出现慢性心肌病变。
3.胃肠道反应有恶心、呕吐、厌食、胃炎、腹泻等,发生率较阿霉素低。其他尚有脱发、皮肤色素沉着、发热、乏力、皮炎。静注时外漏可引起静脉炎,甚至组织坏死。

表阿霉素应用领域 

用途    葸环类抗肿瘤抗生素,广谱。可迅速透入细胞,进入细胞核,抑制核酸的合成和有丝分裂。用于乳癌、恶性淋巴癌、软组织肉瘤、胃癌、恶性黑色素瘤、结肠直肠癌、卵巢癌、肺癌等。

表阿霉素用途     

用于抗肿瘤
生产方法      化合物(I)经三氟乙酸酐N-酰化,以对氨基进行保护,得到化合物(Ⅱ)。再氧化为酮(Ⅲ),然后还原为醇(Ⅳ)。在酸作用下去除醚键,再经三氟乙酸酐酯化为化合物(Ⅵ),然后进行选择性氯代,得到所需的侧链(VII)。
化合物(Ⅷ)经二甲缩丙酮反应成缩酮(Ⅸ),然后和上述制得的侧链(Ⅶ)反应,得到的化合物(X)水解,即得表柔比星。
静脉或动脉内注射,临用前加生理盐水溶解成2mg/ml浓度。静脉滴注,加100ml~250ml生理盐水点滴。成人常用量为每疗程按体表面积60mg~90mg/m2,可1次给予

表阿霉素用法用量

8日等分给药,3周~4周后重复(腔内化疗可于2周~3周后重复)。联合化疗时一般可用单剂量的2/3。总剂量不宜超过700mg/m2,儿童用量约为成人量的1/3~1/2。腹腔内化疗,60mg~80mg/次,联合应用顺铂氟尿嘧啶丝裂霉素,特别是大容量腹腔内化疗可提高疗效。动脉内给药,60mg~80mg/次,也宜联合用药,特别是同用顺铂,1次/1月~3月。胸腔内或膀恍内给药,50mg~60mg/次,前者可与顺铂同用但胃肠道反应则明显增加,大多需于用药前静脉给予血清素受体抑制剂和地塞米松,以避免立时可能出现的恶心、呕吐。

药物相互作用

1.应避免与其他药物放在同一容器内给药; 
2.不能与肝素混合,以免造成沉淀; 
3.与氨茶碱接触可使溶液变成蓝色; 
4.不能与皮质激素类同时滴注;
5.与头孢菌素类接触可引起沉淀;
6.不能与碱性药物或溶液长期接触;
7.与其他蒽环类抗癌抗生素可产生交叉耐药性;
8.与环磷酰胺、氟尿嘧啶、顺铂有协同作用;
9.腔内化疗如与顺铂同用,虽有较高疗效,但不良反应也较显著;
10.给药期间给予大剂量维生素C、维生素E可减轻心肌毒性; 
11.用药期间不宜进行疫苗接种。

注意事项

1. 孕妇禁用,肝功能不全者应适当减少用量。
2. 口服无效,不能肌注或鞘内给药。
3. 静注时最好在输液后由侧管中冲入,避免药液外渗或漏至皮下组织,否则可引起严重组织损伤和坏死。
4. 药物溶解后可在室温下保存24小时,但应避免阳光直接照射。在4~10℃可保存48 小时。

产品用途
用于抗肿瘤
960化工网为您提供表阿霉素专业化合物百科信息,包括中文名,英文名,分子式,分子量,以及该化合物的CasNo.:56420-45-2,和相关理化性质;并提供了优质生产厂家信息包括厂家名称和联系方式等;| WAP 版:56420-45-2
平台客服 平台客服

平台在线客服